Lv3
212 积分 2025-05-06 加入
Early Use of Tocilizumab Following Cytokine Release Syndrome During CAR-T Therapy for Multiple Myeloma May Be Associated With Fewer Short and Long Term Adverse Cardiovascular Events
6小时前
求助中
Clinical Outcomes in Relapsed DLBCL Patients Approved for CAR-T Therapy-A Single-Centre Study
13天前
已完结
Impact of Baseline Anxiety and Depression on Toxicity and Outcomes after Axicabtagene Ciloleucel, Lisocabtagene Maraleucel, and Tisangenleucel for Patients with Diffuse Large B-cell Lymphoma
13天前
已完结
CLINICAL BIOMARKERS ASSOCIATED with PROGRESSION FREE SURVIVAL to CILTACABTAGENE AUTOLEUCEL in CHINESE PATIENTS with RELAPSED/REFRACTORY MULTIPLE MYELOMA from CARTIFAN-1 STUDY
15天前
已关闭
ENHANCED CAR T-CELL EXPANSION AND DURABLE COMPLETE RESPONSES WITH NKTR-255 PLUS LISOCABTAGENE MARALEUCEL IN RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA
18天前
已关闭
Impact of Pre-Existing Neurocognitive Impairments on Toxicity and Outcomes after Axicabtagene Ciloleucel, Lisocabtagene Maraleucel, and Tisangenleucel for Patients with Diffuse Large B-cell Lymphoma
1个月前
已关闭
Real‑world efficacy of CAR T‑cell therapies: a HealthTree cure hub's study of multiple myeloma patients
1个月前
已完结
皖公网安备34019202002308
